Targeting epidermal growth factor receptor in non-small cell lung cancer: Current advances and perspectives;Ciblage du récepteur au facteur de croissance épidermique dans les cancers bronchiques non à petites cellules en 2007: Mise au point et perspectives

Bulletin du Cancer

Volumn 94, Issue SUPPL. 7, 2007, Pages

  Italiano, Antoine ^a,b   Besse, Benjamin ^a   Planchard, David ^a   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Epidermal growth factor receptor; Non small cell lung cancer; Targeted therapies

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PANITUMUMAB; PEMETREXED; TAXANE DERIVATIVE; VINFLUNINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG TARGETING; DRUG USE; HUMAN; LUNG NON SMALL CELL CANCER; PROTEIN TARGETING; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 36248941486     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0445     Document Type: Review

References (79)

1. Molinié F, Velten M, Remontet L, Bercelli P, et Reseau Francim. Évolution de l'incidence du cancer bronchopulmonaire en France (1978-2000). Rev Pr Mal Respir 2006 ; 23 : 127-34.
2. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003 ; 21 : 2237-46.
3. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer : a randomized trial. JAMA 2003 ; 290 : 2149-58.
4. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer : Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005 ; 366 : 1527-37.
5. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer : a phase III trial Intact 1. J Clin Oncol 2004 ; 22 : 777-84.
6. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer : a phase III trial Intact 2. J Clin Oncol 2004 ; 22 : 785-94.
7. Kelly K, Chansky K, Gaspar LE, Jett JR, Ung Y, Albain S, Crowley JJ, Gandara DR, et al. Updated analysis of SWOG 0023 : a randomized phase III trial of gefitinib versus placebo maintenance after definitive chemoradiation followed by docetaxel in patients with locally advanced stage III non-small cell lung cancer. J Clin Oncol 2007 ; 27 ; abstract 7513.
8. Niho S, Ichinose Y, Tamura T, Yamamoto N, Tsuboi M, Nakagawa K, et al. Results of a randomised Phase III study to compare the overall survival of gefitinib (Iressa) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens. J Clin Oncol 2007 ; 25 ; abstract LBA7509.
9. Williams C, Bepler G, Begum M, Chiappori A, Arora R, Haura E, Antonia S, Extermann M, Simon G. Phase II trial of docetaxel plus gefitinib in elderly (≥ 70 years) patients with advanced stage non-small cell lung cancer (ANSCLC). J Clin Oncol 2007 ; 25 ; abstract 7690.
10. Spigel DR, Hainsworth JD, Burkett ER, Burris HA, Yardley DA, et al. Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status : a Minnie Pearl Cancer Research Network Phase II Trial. Clin Lung Cancer 2005 ; 7 : 127-32.
11. Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer : a phase II study. J Clin Oncol 2006 ; 24 : 64-9.
12. Reck M, Buchholz E, Romer KS, Krutzfeldt K, Gatzemeier U, Mnegold C, et al. Gefitinib monotherapy in chemotherapy-naïve patients with inoperable stage III/IV non-small-cell lung cancer. Clin Lung Cancer 2006 ; 7 : 406-11.
13. Suzuki R, Hasegawa Y, Baba K, Saka H, Saito H, Taniguchi H, et al. A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. Br J Cancer 2006 ; 94 : 1599-603.
14. Lin WC, Chiu CH, Liou JL, Chen YM, Perng RP, Tsai CM. Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung Cancer 2006 ; 54 : 193-9.
15. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non - small-cell lung cancer. J Clin Oncol 2004 ; 22 : 3238-47.
16. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 ; 353 : 123-32.
17. Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA, et al. Erlotinib for frontline treatment of advanced non-small cell lung cancer : a phase II study. Clin Cancer Res 2006 ; 12 : 6049-55.
18. Akerley WL. Erlotinib as first-line treatment for untreated advance stage NSCLC with good prognosis. J Clin Oncol 2006 ; 24 : 408 ; (abs 7178).
19. Jackman DM, Lucca J, Fidias P, Rabin MS, Lynch TJ, Ostler P, et al. A phase II trial of erlotinib in previously untreated elderly patients (70 years) with advanced non-small cell lung cancer. Eur. J. Cancer ;3(Suppl) :325 (abstract 1127).
20. Lilenbaum R, Axerold R, Thomas S, Dowlati A, Seigel L, Albert D, et al. Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer and performance status of 2. J Clin Oncol 2006 ; 24(Suppl.) : 369 ; (abs 7022).
21. Li J, Karlsson MO, Brahmer J, Spitz A, Zhao M, Hidalgo M, et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 2006 ; 98 : 1714-23.
22. Hamilton M, Wolf JL, Zborowski D, Lu J, Lum BL, Ding K, et al. Tarceva (erlotinib) exposure/effects analysis from a phase III study in advanced NSCLC : Effect of smoking on the PK of erlotinib. Proc Am Assoc Cancer Res 2005 : 46 ; (Abstract 6165).
23. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005 ; 97 : 643-55.
24. Hirsch F, McCoy J, Cappuzzo F, Howard Jack W, Gumerlock P, Crino L, et al. FISH and immunohistochemistry can be used to select NSCLC patients, who will not benefit from gefitinib treatment. Lung Cancer 2005 ; 49 : S38 ; (abs O-107).
25. Hirsch FR, Varella-Garcia M, Bunn Jr. PA, Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer. J Clin Oncol 2006 ; 24 : 5034-42.
26. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005 ; 353 : 133-44.
27. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Störkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues : variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004 ; 52 : 893-901.
28. Defize LH, Arndt-Jovin DJ, Jovin TM, Boonstra J, Meisenhelder J, Hunter T, et al. A431 cell variants lacking the blood group A antigen display increased high affinity epidermal growth factor-receptor number, protein-tyrosine kinase activity, and receptor turnover. J Cell Biol 1988 ; 107 : 939-49.
29. Lax I, Bellot F, Howk R, Ullrich A, Givol D, Schlessinger J. Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules. EMBO J 1989 ; 8 : 421-7.
30. King AC, Cuatrecasas P. Resolution of high and low affinity epidermal growth factor receptors : Inhibition of high affinity component by low temperature, cycloheximide, and phorbol esters. J Biol Chem 1982 ; 257 : 3053-60.
31. Defize LH, Boonstra J, Meisenhelder J, Kruijer W, Tertoolen LG, Tilly BC, et al. Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors. J Cell Biol 1989 ; 109 : 2495-507.
32. Bellot F, Moolenaar W, Kris R, Mirakhur B, Verlaan I, Ullrich A, et al. High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses. J Cell Biol 1990 ; 110 : 491-502.
33. Johns TG, Adams TE, Cochran JR, Hall NE, Hoyne PA, Olsen MJ, et al. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 2004 ; 279 : 30375-84.
34. Mattoon D, Klein P, Lemmon MA, Lax I, Schlessinger J. The tethered configuration of the EGF receptor extracellular domain exerts only a limited control of receptor function. Proc Natl Acad Sci USA 2004 ; 101 : 923-8.
35. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 ; 350 : 2129-39.
36. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science 2004 ; 304 : 1497-500.
37. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006 ; 118 : 257-62.
38. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from «never smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004 ; 101 : 13306-11.
39. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer : molecular analysis of the Ideal/Intact gefitinib trials. J Clin Oncol 2005 ; 23 : 8081-92.
40. Chou TY, Chiu CH, Li LH, Hsiao CY, Tzen CY, Chang KT, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 2005 ; 11 : 3750-7.
41. Cortes-Funes H, Gomez C, Rosell R, Valero P, Garcia-Giron C, Velasco A, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 2005 ; 16 : 1081-6.
42. Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005 ; 23 : 2493-501.
43. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004 ; 10 : 8195-203.
44. Kim KS, Jeong JY, Kim YC, Na KJ, Kim YH, Ahn SJ, et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 2005 ; 11 : 2244-51.
45. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005 ; 23 : 2513-20.
46. Mu XL, Li LY, Zhang XT, Wang SL, Wang MZ. Evaluation of safety and efficacy of gefitinib (Iressa, zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer : experience from a compassionate-use programme. BMC Cancer 2004 ; 4 : 51.
47. Tokumo M, Toyooka S, Kiura K, Shigematsu H, Tomii K, Aoe M, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005 ; 11 : 1167-73.
48. Kondo M, Yokoyama T, Fukui T, Yoshioka H, Yokoi K, Nagasaka T, et al. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Lung Cancer 2005 ; 50 : 385-91.
49. Rosell R, Ichinose Y, Taron M, Sarries C, Queralt C, Mendez P, et al. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer 2005 ; 50 : 25-33.
50. Shih JY, Gow CH, Yu CJ, Yang CH, Chang YL, Tsai MF, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced non small cell lung cancer. Int J Cancer 2006 ; 118 : 963-9.
51. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005 ; 11 : 5878-85.
52. Tomizawa Y, Iijima H, Sunaga N, Sato K, Takise A, Otani Y, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005 ; 11 : 6816-22.
53. Uramoto H, Sugio K, Oyama T, Ono K, Sugaya M, Yoshimatsu T, et al. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer 2006 ; 51 : 71-7.
54. Zhang XT, Li LY, Mu XL, Cui QC, Chang XY, Song W, et al. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol 2005 ; 16 : 1334-42.
55. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006 ; 24 : 3340-6.
56. Morikawa A, Inoue A, Suzuki T, Fukuhara T, Suzuki S, Kondo T, et al. Prospective analysis of the epidermal growth factor receptor gene mutations in non-small cell lung cancer in Japan. J Clin Oncol 2006 ; 24 : 18S ; (abstract 7077).
57. Paz-Ares L, Sanchez JM, Garcia-Velasco A, Massuti B, López-Vivanco G, Provencio M, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer patients with mutations in the tyrosine kinase domain of the epidermal growth factor receptor. J Clin Oncol 2006 ; 24 : 18S ; (abstract 7020).
58. Sunaga N, Yanagitani N, Kaira K, Tomizawa Y, Iijima H, Otani Y, et al. Phase II study of the efficacy of gefitinib in patients with non-small cell lung cancer with the EGFR mutations. J Clin Oncol 2006 ; 24 : 18S ; (abstract 7183).
59. Sutani A, Nagai Y, Udagawa K, Uchida Y, Murayama Y, Tanaka T, et al. Phase II study of gefitinib for non-small cell lung cancer patients with epidermal growth factor receptor gene mutations detected by PNA-LNA PCR clamp. J Clin Oncol 2006 ; 24 : 18S ; (abstract 7076).
60. Sequist LV, Martins RG, Spigel D, Grunberg SM, Jänne PA, McCollum D, et al. iTARGET: A phase II trial to assess the response to gefitinib in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) tumors. J Clin Oncol 2007 ; 25 ; abstract 7504.
61. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. Tribute : a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005 ; 23 : 5892-9.
62. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005 ; 97 : 339-46.
63. Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006 ; 12 : 839-44.
64. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006 ; 12 : 3908-14.
65. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005 ; 352 : 786-92.
66. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005 ; 102 : 7665-70.
67. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005 ; 2 : 1-11.
68. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007 ; 13 : 2890-6.
69. Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas : correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003 ; 21 : 3798-807.
70. Italiano A, Vandenbos FB, Otto J, Mouroux J, Fontaine D, Marcy PY, et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites : implications for treatment with EGFR-inhibitors. Ann Oncol 2006 ; 17 : 981-5.
71. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004 ; 64 : 7241-4.
72. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005 ; 23 : 6829-37.
73. Shepherd FA, Ding K, Sakurada A, Da Cunha Santos G, Zhu C, Seymour L, et al. Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene and codons 12 and 13 of the KRAS gene in non-small cell lung cancer (NSCLC) patients treated with erlotinib in National Cancer Institute of Cancer. J Clin Oncol 2007 ; 25 ; abstract 7571.
74. Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Janne PA, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006 ; 24 : 5253-8.
75. Kim ES, Mauer AM, Tran HT, Liu D, Gladish G, Dicke K, et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer : Final report. Proc Am Soc Clin Oncol 2003 ; 22 : 642 ; (abstr 2581).
76. Rosell R, Daniel C, Ramlau R, Szczesna A, Constenla M, Mennecier B, et al. Randomized phase II study of cetuximab in combination with cisplatin and vinorelbine vs. CV alone in the first-line treatment of patients with epidermal growth factor receptor-expressing advanced non-small-cell lung cancer. J Clin Oncol 2004 ; 22 : 14S ; (abstract 7012).
77. Butts CA, Bodkin D, Middelman EL, Englund CW, Ellison D, Alam YZ, et al. Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007 ; 25 ; abstract 7539.
78. Crawford J, Sandler AB, Hammond LA, Schiller J, Belani C, Kozloff M, et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer. J Clin Oncol 2004 ; 22 : 14S ; (abstract 7083).
79. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kirn ES, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005 ; 23 : 2544-55.